Leavell Investment Management Inc. Invests $32,000 in 23andMe Holding Co. (NASDAQ:ME)

Leavell Investment Management Inc. purchased a new position in 23andMe Holding Co. (NASDAQ:ME) in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund purchased 10,000 shares of the company’s stock, valued at approximately $32,000.

Other hedge funds have also recently modified their holdings of the company. FNY Investment Advisers LLC purchased a new stake in 23andMe during the fourth quarter valued at $26,000. MassMutual Private Wealth & Trust FSB purchased a new stake in 23andMe during the fourth quarter valued at $40,000. AQR Capital Management LLC increased its position in 23andMe by 145.8% during the second quarter. AQR Capital Management LLC now owns 444,222 shares of the company’s stock valued at $174,000 after acquiring an additional 263,468 shares during the last quarter. FMR LLC increased its position in 23andMe by 24.0% during the third quarter. FMR LLC now owns 993,848 shares of the company’s stock valued at $345,000 after acquiring an additional 192,099 shares during the last quarter. Finally, GSA Capital Partners LLP purchased a new stake in 23andMe during the third quarter valued at $805,000. Hedge funds and other institutional investors own 36.10% of the company’s stock.

Analyst Ratings Changes

Separately, Weiss Ratings reiterated a “sell (e+)” rating on shares of 23andMe in a research report on Saturday, February 1st.

23andMe Stock Performance

NASDAQ:ME opened at $2.55 on Friday. The stock has a 50-day simple moving average of $3.30 and a two-hundred day simple moving average of $4.83. 23andMe Holding Co. has a 52-week low of $2.42 and a 52-week high of $16.52. The firm has a market capitalization of $66.61 million, a PE ratio of -0.17 and a beta of 1.14.

23andMe (NASDAQ:ME) last released its quarterly earnings results on Tuesday, January 28th. The company reported ($1.02) earnings per share (EPS) for the quarter. 23andMe had a negative net margin of 183.39% and a negative return on equity of 145.99%.

About 23andMe

23andMe Holding Co operates as a consumer genetics testing company. The company operates in two segments, Consumer & Research Services and Therapeutics. The Consumer & Research Services segment provides a suite of genetic reports, including information on customers' genetic ancestral origins, personal genetic health risks, and chances of passing on certain rare carrier conditions to their children, as well as reports on how genetics can impact responses to medications.